Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
NVCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.91 - $34.13
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.71M
Market Cap
$1.27B
Enterprise Value$1.77B
Total Cash (Recent Filing)$911.52M
Total Debt (Recent Filing)$700.25M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Oct 23, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding111,799,290
10 Day Avg. Volume2,759,903
30 Day Avg. Volume1,709,505
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit3.68
Enterprise Value/Ebitda-16.00
Forecast
1Y Price Target
$26.50Price Target Upside131.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial Performance2Q25 revenues beat consensus estimates, primarily driven by active patient growth across major markets.
Regulatory ProgressThe company noted a high likelihood of FDA approval for the PANOVA-3 Phase 3 trial, which could positively impact the company's product pipeline.
Bears Say
Mixed Product LaunchThe disclosed metrics on the early lung cancer launch were mixed.
Prescriber EngagementThe number of unique prescribers decreased to 75 in 2Q from 93 in 1Q25, indicating a reduction in the number of doctors prescribing the treatment.
NovoCure News
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $10.91 and its highest was $34.13 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $1.27B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Oct 23, 2025 which is in 77 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Jul 24, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.384 by $0.024.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.42.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 111,799,290 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.384. Following the earnings report the stock price went down -24.046%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in NVCR
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.50 (131.85% Upside)
$26.50 (131.85% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 774.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $231.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.18%
12-Months-Change
Fundamentals
Return on Equity
-48.07%
Trailing 12-Months
Asset Growth
2.78%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NVCR Company Deck
NVCR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Novocure's earnings call highlighted significant clinical trial successes and ongoing growth in its GBM business, alongside the initial progress of its Optune Lua launch. However, challenges such as lower gross margins, a net loss, and slower than expected Optune Lua adoption were noted. The sentiment is cautiously optimistic, with clear potential for future growth once new indications are launched and reimbursement is established.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$26.50
▲(131.85% Upside)
Technical Analysis
Ownership Overview
2.35% Insiders
32.63% Mutual Funds
0.18% Other Institutional Investors
48.80% Public Companies and Individual Investors